Technical Analysis for COLL - Collegium Pharmaceutical, Inc.

Grade Last Price % Change Price Change
grade F 11.97 -4.32% -0.54
COLL closed down 4.32 percent on Monday, May 20, 2019, on approximately normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical COLL trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -4.32%

Older signals for COLL ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, focuses on developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its lead product candidate is Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone, a prescribed opioid medication. The company is also developing COL-172, an abuse-deterrent, extended-release oxymorphone for the treatment of chronic pain; COL-195, an abuse-deterrent, extended-release hydrocodone for the treatment of chronic pain; COL-196, a morphine formulation for the treatment of pain; and COL-171, a proprietary preclinical DETERx extended-release, abuse-deterrent methylphenidate formulation for the treatment of attention deficit hyperactivity disorder. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Canton, Massachusetts.
Pharmaceutical Pain Diseases Chemical Compounds Organic Compounds Euphoriants Chronic Pain Morphinans Platform Technology Attention Deficit Hyperactivity Disorder Ethers Opioids Phenols Hydrocodone Treatment Of Attention Deficit Hyperactivity Disorder Oxycodone Oxymorphone
Is COLL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 28.91
52 Week Low 11.94
Average Volume 379,524
200-Day Moving Average 16.1863
50-Day Moving Average 15.163
20-Day Moving Average 13.9235
10-Day Moving Average 13.428
Average True Range 0.7828
ADX 20.52
+DI 12.9396
-DI 29.7209
Chandelier Exit (Long, 3 ATRs ) 13.0016
Chandelier Exit (Short, 3 ATRs ) 14.2884
Upper Bollinger Band 15.5685
Lower Bollinger Band 12.2785
Percent B (%b) -0.09
BandWidth 23.629116
MACD Line -0.6951
MACD Signal Line -0.5344
MACD Histogram -0.1607
Fundamentals Value
Market Cap 353.91 Million
Num Shares 29.6 Million
EPS -3.59
Price-to-Earnings (P/E) Ratio -3.33
Price-to-Sales 40.60
Price-to-Book 3.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.78
Resistance 3 (R3) 12.86 12.67 12.65
Resistance 2 (R2) 12.67 12.46 12.63 12.60
Resistance 1 (R1) 12.32 12.34 12.23 12.24 12.55
Pivot Point 12.13 12.13 12.08 12.09 12.13
Support 1 (S1) 11.78 11.92 11.69 11.70 11.39
Support 2 (S2) 11.59 11.80 11.55 11.34
Support 3 (S3) 11.24 11.59 11.30
Support 4 (S4) 11.16